Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-07-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: transplantationstagepatientinductionhours
  Phrases that lowered it: evaluate theto evaluatethe effecteffect ofkg
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 8.6% (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 30.1% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 64 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 94.0% (raises risk) · Drug's FDA history
• Sponsor's past trials: 291 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports before start: 2848 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes NCT01606787 · started 2012 · scored riskier than 36% of active trials completed
• The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial NCT04251689 · started 2018 · scored riskier than 57% of active trials completed
• The Comparison Between Ringer Lactate Solution and Normal Saline With Dextrose Water in Post-Operative Period of Kidney Transplantation NCT06030609 · started 2024 · scored riskier than 15% of active trials completed
• Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension NCT01520207 · started 2012 · scored riskier than 49% of active trials completed
• The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients NCT05232370 · started 2022 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.